TROP2 ADC Intrigues in NSCLC

Abstract The TROP2-directed antibody–drug conjugate datopotamab deruxtecan may be active in patients with advanced or metastatic non–small cell lung cancer, according to preliminary findings. In a phase I trial, the agent elicited responses in almost a quarter of patients and had manageable side effects.